

FDA approves Novartis Vioice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)

Apr 06, 2022

Source URL: <https://qa1.novartis.us/news/media-releases/fda-approves-novartis-vioice-alpelisib-first-and-only-treatment-select-patients-pik3ca-related-overgrowth-spectrum-pros-0>

List of links present in page

1. <https://qa1.novartis.us/news/media-releases/fda-approves-novartis-vioice-alpelisib-first-and-only-treatment-select-patients-pik3ca-related-overgrowth-spectrum-pros-0>